Austar Lifesciences forecasts 60–68% interim profit decline amid margin pressure and higher promotion costs

Bulletin Express07-30

Austar Lifesciences Limited expects profit attributable to owners for the six months ended 30 June 2026 to range between RMB8.00 million and RMB10.00 million, according to a preliminary assessment of unaudited management accounts disclosed on 30 July 2026. This compares with RMB25.00 million in the prior-year period, implying a year-on-year contraction of roughly 60%–68%.

Management attributes the lower earnings to three primary factors:

1. A non-recurrence of the RMB11.40 million one-off foreign-exchange gain recorded in first-half 2025. 2. Gross-margin compression linked to the execution of several strategic projects. 3. Higher operating expenses incurred for market-promotion activities undertaken during an accelerated market-expansion phase.

The interim results are still being finalised and remain subject to review by both external auditors and the board’s audit committee. Austar Lifesciences plans to release its full interim report in late August 2026. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1175116375?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-30 17:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175116375","market":"hk","top_or_hot":-1,"title":"Austar Lifesciences forecasts 60–68% interim profit decline amid margin pressure and higher promotion costs","media":"Bulletin Express","content":"<p>Austar Lifesciences Limited expects profit attributable to owners for the six months ended 30 June 2026 to range between RMB8.00 million and RMB10.00 million, according to a preliminary assessment of unaudited management accounts disclosed on 30 July 2026. This compares with RMB25.00 million in the prior-year period, implying a year-on-year contraction of roughly 60%–68%.</p>\n<p>Management attributes the lower earnings to three primary factors:</p>\n<p>1. A non-recurrence of the RMB11.40 million one-off foreign-exchange gain recorded in first-half 2025.  \n2. Gross-margin compression linked to the execution of several strategic projects.  \n3. Higher operating expenses incurred for market-promotion activities undertaken during an accelerated market-expansion phase.</p>\n<p>The interim results are still being finalised and remain subject to review by both external auditors and the board’s audit committee. Austar Lifesciences plans to release its full interim report in late August 2026. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Austar Lifesciences forecasts 60–68% interim profit decline amid margin pressure and higher promotion costs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAustar Lifesciences forecasts 60–68% interim profit decline amid margin pressure and higher promotion costs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-30 17:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Austar Lifesciences Limited expects profit attributable to owners for the six months ended 30 June 2026 to range between RMB8.00 million and RMB10.00 million, according to a preliminary assessment of unaudited management accounts disclosed on 30 July 2026. This compares with RMB25.00 million in the prior-year period, implying a year-on-year contraction of roughly 60%–68%.</p>\n<p>Management attributes the lower earnings to three primary factors:</p>\n<p>1. A non-recurrence of the RMB11.40 million one-off foreign-exchange gain recorded in first-half 2025.  \n2. Gross-margin compression linked to the execution of several strategic projects.  \n3. Higher operating expenses incurred for market-promotion activities undertaken during an accelerated market-expansion phase.</p>\n<p>The interim results are still being finalised and remain subject to review by both external auditors and the board’s audit committee. Austar Lifesciences plans to release its full interim report in late August 2026. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06118","symbol_name":"奥星生命科技","start_time":0,"source_url":"","article_id":"1175116375","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175116375","pubTimestamp":1785402235,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Austar Lifesciences Limited expects profit attributable to owners for the six months ended 30 June 2026 to range between RMB8.00 million and RMB10.00 million, according to a preliminary assessment of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06118":"奥星生命科技"},"translate_title":"由于利润率压力和促销成本上升，Austar Lifesciences 预计中期利润将下降 60-68%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06118":1},"content_text":"Austar Lifesciences Limited expects profit attributable to owners for the six months ended 30 June 2026 to range between RMB8.00 million and RMB10.00 million, according to a preliminary assessment of unaudited management accounts disclosed on 30 July 2026. This compares with RMB25.00 million in the prior-year period, implying a year-on-year contraction of roughly 60%–68%.\nManagement attributes the lower earnings to three primary factors:\n1. A non-recurrence of the RMB11.40 million one-off foreign-exchange gain recorded in first-half 2025.  \n2. Gross-margin compression linked to the execution of several strategic projects.  \n3. Higher operating expenses incurred for market-promotion activities undertaken during an accelerated market-expansion phase.\nThe interim results are still being finalised and remain subject to review by both external auditors and the board’s audit committee. Austar Lifesciences plans to release its full interim report in late August 2026. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1175116375","isCrawlerRequest":true}